TNFα Monoclonal Antibody for Acute Spinal Cord Injury
- Conditions
- Spinal Cord Injuries
- Interventions
- Registration Number
- NCT04988425
- Lead Sponsor
- Shanghai Changzheng Hospital
- Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of subcutaneous injection of TNFα monoclonal antibody cells for the treatment of traumatic acute spinal cord injury. Spinal cord injury can be divided into three phases, which are acute (within 2 weeks), sub-acute (2 weeks to 6 months), and chronic (over 6 months). The pathological process of spinal cord injury include primary injury (initial traumatic insult) and a progressive secondary injury cascade characterized by ischemia, proapoptotic signaling, peripheral inflammatory cell infiltration and the release of proinflammatory cytokines. Secondary injury plays a key role in the loss of spinal cord function after trauma. So early treatment to prevent the secondary injury is the key to improve prognosis. TNFα monoclonal antibody is a TNF-α inhibitor that could control inflammatory response, and now widely used in the treatment of Ankylosing spondylitis, Rheumatoid arthritis and other autoimmune diseases. In this study, the investigators will treat patients with acute spinal cord injury with TNFα monoclonal antibody and compare with the control group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
- Patients aged between 18 and 60 years
- Traumatic spinal cord injury
- ASIA Impairment Scale A-D
- The injury must be within two weeks
- Patients submitted written informed consent
- Traumatic spinal cord injury with brain injury or peripheral nerve injury
- Patients with severe multiple injuries and unstable vital signs
- Non-traumatic spinal cord injury caused by spinal tumors, hematoma, myelitis, etc.
- Patients with central spinal cord injury
- Patients with a completely transected spinal cord
- Patients with fever or acute infection
- Ongoing infectious disease, such as tuberculosis, HIV, hepatitis, syphilis, etc.
- Patients with malignant tumour
- Patients with neurodegenerative diseases, or any neuropathies
- Patients with ankylosing spondylitis
- Patients with a previous history of spinal surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Saline Injection of the same volume of saline immediately after admission before surgery. TNFα monoclonal antibody group TNFα Monoclonal Antibody Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery. Methylprednisolone group Methylprednisolone Injection of 500mg of methylprednisolone immediately after admission before surgery.
- Primary Outcome Measures
Name Time Method American Spinal Injury Association Impairment Scale(ASIA) baseline, 1 month, 3 months, 6 months and 12 months post-treatment Change in sensory and motor function as measured by the American Spinal Injury Association Impairment Scale (ASIA). The scale ranked from A to E, A indicates the the most severe spinal cord injury and E indicates no neurological deficit.
- Secondary Outcome Measures
Name Time Method Motor Evoked Potentials (MEP) and Somatosensory Evoked Potentials (SSEP) test baseline, 3 months, 6 months and 12 months post-treatment Change in sensory and motor function will be measured by SSEP and MED test
Residual urine test baseline, 3 months, 6 months and 12 months post-treatment Change in residual urine as measured by ultrasound test
Incidence of adverse events 1 month post-treatment Any abnormal signs, symptoms, findings, or diseases that emerge or worsen relative to baseline in 1 month posttreatment will be recorded as adverse event
Trial Locations
- Locations (1)
Shanghai Changzheng Hospital
🇨🇳Shanghai, China